Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607; SHA: 601607) announced that it has renewed its Sales and Distribution Agreement with Shanghai Fudan‑Zhangjiang Bio‑Pharmaceutical Co., Ltd. (HKG: 1349). Under the agreement, running from 1 January 2027 to 31 December 2029, Fudan‑Zhangjiang has appointed Shanghai Pharmaceuticals to provide sales services for its pharmaceutical products, with annual transaction caps of RMB 86 million (2027), RMB 90 million (2028), and RMB 96 million (2029).
Deal Overview
| Item | Detail |
|---|---|
| Parties | Shanghai Pharmaceuticals Holding Co., Ltd. (SHA: 601607) and Shanghai Fudan‑Zhangjiang Bio‑Pharmaceutical Co., Ltd. (HKG: 1349) |
| Announcement Date | 30 Oct 2026 |
| Agreement Type | Renewed Sales and Distribution Agreement – sales services for pharmaceutical products |
| Term | 1 Jan 2027 – 31 Dec 2029 (three years) |
| Annual Cap – 2027 | Not to exceed RMB 86 million |
| Annual Cap – 2028 | Not to exceed RMB 90 million |
| Annual Cap – 2029 | Not to exceed RMB 96 million |
| Products Covered | Fudan‑Zhangjiang pharmaceutical products (specific list not disclosed) |
Partnership Profile
- Structure: Fudan‑Zhangjiang, as product owner, has appointed Shanghai Pharmaceuticals – one of China’s largest pharmaceutical distribution groups – to provide sales services for its pharmaceutical products, covering commercialization reach into China’s hospital and retail channels.
- Continuity: The renewal extends an existing commercial relationship, signaling both parties’ satisfaction with the prior agreement’s execution and providing three more years of defined cooperation.
- Cap Discipline: The annual caps rise modestly year over year (approximately +5% and +7% across 2027–2029), setting a controlled, board‑approved envelope for the related transaction flow.
- Strategic Fit: For Fudan‑Zhangjiang, the arrangement leverages Shanghai Pharmaceuticals’ nationwide distribution infrastructure instead of building proprietary sales capacity; for Shanghai Pharmaceuticals, it adds branded products to its distribution and services portfolio.
Market Impact & Outlook
- Stable Commercial Channel: Locking in the sales arrangement through 2029 gives Fudan‑Zhangjiang predictable market access for its products while Shanghai Pharmaceuticals secures incremental service revenue within the capped limits.
- Distribution Scale Advantage: The partnership reinforces Shanghai Pharmaceuticals’ position as a preferred commercialization partner for Shanghai‑based innovators seeking nationwide reach.
- Governance Transparency: Publishing three‑year annual caps of RMB 86/90/96 million provides investors with a clear ceiling on transaction exposure under the renewed framework.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the renewed sales and distribution cooperation between Shanghai Pharmaceuticals and Fudan‑Zhangjiang, including product sales performance within the stated annual caps for 2027–2029. Actual results may differ materially due to risks including market demand, pricing and procurement policy changes, distribution execution, and the terms of any subsequent amendments. Figures are as reported in the company’s 30 Oct 2026 announcement.-Fineline Info & Tech
